#xeljanz

[kinkykinard]

they've got to stop coming up with new medications and naming them like they're world of warcraft villains

[thymogam]

Buy Tofacitinib (Xeljanz) Medicine | Tofacitinib Cost in India

Tofacitinib (Xeljanz), a Janus kinase (JAK) inhibitor, is used to treat psoriatic arthritis, ulcerative colitis, and rheumatoid arthritis. Headache, diarrhoea, and high blood pressure are all common side effects. To find out how much tofacitinib costs in India, contact The Indian Pharma at 1-800-889-1064 or call/whatsapp +91 8130290915. The Indian Pharma (TIP) is a pharmaceutical consulting firm that specialises in providing medicines under the Named Patient Program (NPP)/Manage Access Program (MAP). TIP connects the buyer with a Tofacitinib supplier who can ship XELJANZ (Tofacitinib 5 mg) to any country in the world based on the buyer's requirements and local government regulations.

[the-prophesied-disco-gay]

I have Ankylosing Spondylitis too! It was Xeljanz for me! I just today got the very first ALL withing normal range blood test results I have ever had in my entire life. Ever. The Vitamin y'all

My deepest darkest fantasy is that I collapse on the street and I am rushed to the hospital. They perform a bunch of tests and find out I am severely deficient in some kind of vitamin. Then I start taking the vitamin and I become the happiest cleverest person alive because all my problems were caused by this one deficiency

[dermatologyclinicaltrials]

Clinical Trials in Atopic Dermatitis: Advancements, Challenges, and Future Prospects

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition that affects millions of individuals worldwide, particularly children. Characterized by dry, itchy skin, and recurrent flare-ups, AD can significantly impact a person's quality of life. The condition is associated with a variety of triggers such as allergens, irritants, and stress, and while its exact cause remains unknown, genetic and environmental factors play a significant role. Despite the growing understanding of the disease, effective treatments have been limited, which has driven the need for clinical trials focused on advancing therapeutic options.

Understanding Atopic Dermatitis

Atopic dermatitis is often diagnosed in early childhood and can persist into adulthood, although its severity tends to fluctuate over time. The primary symptoms include intense itching (pruritus), erythema (redness), and inflammation, which can lead to skin infections if left untreated. Additionally, patients with AD may experience sleep disturbances and emotional distress due to the constant discomfort and visible nature of the condition. The disease is often associated with other allergic conditions, such as asthma and allergic rhinitis, forming part of what is known as the "atopic march."

The underlying pathophysiology of AD is complex and involves a combination of genetic, immune, and environmental factors. Key features include a dysfunctional skin barrier, an overactive immune response, and microbial dysbiosis (imbalance in the skin's microbiome). As a result, the skin becomes more vulnerable to irritants and allergens, leading to inflammation and exacerbating the condition. Understanding these mechanisms has been instrumental in developing targeted therapies.

The Role of Clinical Trials in Advancing AD Treatment

Clinical trials atopic dermatitis are fundamental in advancing the understanding and treatment of atopic dermatitis. Historically, treatment options were limited to topical corticosteroids and antihistamines, which helped manage symptoms but did not address the underlying causes of the disease. In recent years, however, significant strides have been made in the development of new therapies, many of which have emerged from clinical trials. These trials explore the efficacy and safety of new drugs, biologics, and non-pharmacological treatments.

Several promising treatments for AD have been developed as a result of clinical trials. For example, biologics such as dupilumab (Dupixent) have revolutionized the management of moderate to severe AD. Dupilumab, an interleukin-4 (IL-4) and IL-13 inhibitor, works by targeting specific cytokines involved in the inflammatory process of AD. Clinical trials have demonstrated that dupilumab significantly reduces disease severity, improves quality of life, and is generally well-tolerated by patients. The approval of dupilumab marked a milestone in the treatment of AD, offering a new option for patients with inadequately controlled disease.

Another area of focus in clinical trials for AD is the development of Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and abrocitinib (Cibinqo). JAK inhibitors work by targeting specific enzymes that contribute to the inflammatory processes in AD. Clinical trials have shown that these drugs can rapidly reduce symptoms and improve skin clearance, making them a promising treatment for patients with moderate to severe AD who do not respond to traditional therapies.

Challenges in Atopic Dermatitis Clinical Trials

Despite the significant progress made in developing new treatments, clinical trials for AD face several challenges. One of the major obstacles is the heterogeneity of the disease. AD manifests differently in each patient, and its severity can vary greatly between individuals. This variability makes it difficult to design and conduct trials that can accurately assess the efficacy of a treatment across diverse patient populations. Furthermore, the chronic and relapsing nature of the disease complicates trial design, as the effects of treatment may not always be immediately apparent.

Patient recruitment is another significant challenge. Many clinical trials for AD focus on moderate to severe cases, but recruiting enough patients who meet the strict inclusion criteria can be difficult. Additionally, the duration of clinical trials, which can span several months or even years, presents challenges in retaining participants, particularly in trials that involve long-term follow-up to assess the durability of treatment effects.

There are also ethical considerations in conducting clinical trials for AD. Since the disease causes significant discomfort and affects patients' quality of life, it is important to ensure that patients enrolled in clinical trials are not deprived of effective treatment. This issue is particularly relevant in placebo-controlled trials, where participants may not receive the active treatment. To address this, many trials employ an "escape clause" that allows patients to receive the active treatment if their condition worsens or if they experience intolerable side effects from the placebo.

Future Prospects for Atopic Dermatitis Clinical Trials

The future of clinical trials in atopic dermatitis looks promising, with continued advancements in both treatment options and trial design. The growing understanding of the molecular mechanisms underlying AD is paving the way for more targeted therapies that address the root causes of the disease rather than just its symptoms. Biologics targeting specific immune pathways, such as IL-13, IL-31, and TSLP (thymic stromal lymphopoietin), are being explored in clinical trials, with the potential to offer even more effective treatments for patients with severe disease.

In addition to pharmacological therapies, clinical trials are also investigating non-pharmacological approaches to managing AD. These include advances in skin barrier repair, microbiome modulation, and dietary interventions. For example, studies are exploring the role of prebiotics and probiotics in restoring balance to the skin microbiome and reducing inflammation. Furthermore, researchers are investigating the use of phototherapy (light therapy) as a treatment option, especially for patients who do not respond well to topical or systemic therapies.

Moreover, advancements in trial design and technology are helping to improve the efficiency and outcomes of AD clinical trials. The use of digital tools, such as mobile apps and wearable devices, can enable real-time monitoring of symptoms and treatment effects, providing more accurate data and improving patient adherence to the trial protocol. Adaptive trial designs, which allow for modifications to the trial based on interim results, are also becoming more common, enabling researchers to make more informed decisions during the trial process.

Conclusion

Clinical trials have played a crucial role in advancing the treatment of atopic dermatitis, leading to the development of new therapies that offer significant improvements in disease management. While challenges remain, such as patient recruitment and disease heterogeneity, ongoing research holds promise for the continued evolution of AD treatments. With the advent of targeted biologics, JAK inhibitors, and other innovative approaches, the future of atopic dermatitis treatment is bright, offering hope for improved quality of life for patients affected by this chronic and often debilitating condition.

[genericmedicinechem]

Tofacitinib (often marketed under brand names such as Xeljanz) is a medication used to treat certain autoimmune conditions. The 5 mg tablet of tofacitinib is typically prescribed for conditions like rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis.

Tofacitinib works by inhibiting Janus kinase (JAK) enzymes, which play a role in the inflammatory process. By blocking these enzymes, the medication helps to reduce inflammation and symptoms associated with these conditions.

[near-seth-experience]

Over the past 6 years with psoriatic arthritis, I wouldn't be surprised if I've forgotten some on this list, but I've tried:

Methotrexate (stopped due to high liver function)

Otezla (didn't work)

Enbrel (didn't work)

Humira (worked for a little while)

Rinvoq (made me nauseous immediately, only lasted a week)

Taltz (didn't work)

Xeljanz (didn't work)

Skyrizi (Only got my loading doses before life got in the way and American Healthcare™ made it impossible for me to continue treatment. It was too soon to tell if it actually helped.)

Today the Rheumatologist decided that after all the stress I got from just trying to get back on Skyrizi, we're not bothering with it anymore. Next up is Remicade. Apparently it's an IV infusion? I've only been hooked up to an IV once berfore that I can remember, so I'm a little nervous about it tbh. He said it might be easier for my (shitty) insurance to authorize, and since I have to go in to the clinic in order have it done, it seems like I don't need to worry about going through specialty pharmacies or copay assistance programs.

If there's fewer hoops for me to jump through to in order to actually receive treatment, I'm all for it.

[ikrispharmaa]

Ikris Pharmaceutical in Brazil Health sector

We, Ikris Pharma International, are pharmaceutical distributors from Bulgaria. We supply products to all the people involved in the supply chain of Healthcare distribution throughout the world. We supply medicines and other medical products to wholesalers, distributors, resellers, clinics, NGOs and Pharmacies. Ikris is a GDP certified company having licenses for both wholesale and retail drugs. The supply chain of Healthcare distribution is different from other industries. Each product needs different storage conditions. We do not compromise with the quality of the product hence we store and transport them under required storage conditions.

In the Brazil Health sector, Ikris Pharma is reaching new heights in supplying medicines and medical aids from India to Brazil from the previous two years. Especially during the Coronavirus pandemic outbreak, Ikris Pharma gave its best shot to supply medicines and services in Brazil when most of the transportation facilities were at halt. Being the international pharmaceutical wholesaler and distributor we supply at global level with best quality products. India is one of the largest producers and providers of generic drugs at global level. We have the highest number of FDA approved manufacturing plants in the world. As Ikris Pharma, we specialize in exporting generic medicines from India to across the world. Our all products are manufactured by certified and reputed Indian manufacturers, compatible and consistent with FDA standards.

Ikris Pharma helps patients / Clinicians and Hospitals in accessing Indian generic medicine and specialized medicines which are used in rare diseases. Ikris Pharma has supplied more than 100+ products to patients / Hospitals in Brazil. Here are some of our product supplied in Brazil:

We deal in numerous medicines related to oncology (different kinds of cancers), hematology (leukemia and lymphoma, multiple myeloma), hepatitis (hepatitis B, hepatitis C), immunotherapy (eliglustat, xeljanz, etc.), transplant medicine, vaccines (such as cholera vaccine, ONCO BCG, etc.). We are aiming to supply every kind of rare medicine in Brazil.

We are becoming a major pharmaceutical supplier in Brazil, with time we are aiming to become the most reliable and trustworthy supplier of pharmaceutical products to Brazil and other Latin American markets. We understand the needs of the patient, our turnaround time is less. We supply medicine at the shortest possible time. And we do business with one mantra that is each life counts and is precious for us. We have been in this Pharmaceutical business for 25 plus years as one of the trusted brands in the supply chain of medicinal products overseas.

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0102/2023 #BioTech #science

[ocombatenterondonia]

Fiocruz firma acordo que torna acessível tratar artrite reumatoide

O Instituto de Tecnologia em Fármacos (Farmanguinhos/Fiocruz) assinou acordo de transferência tecnológica para produção do medicamento citrato de tofacitinibe, clone genérico do Xeljanz®. A parceria foi firmada com a Pfizer Brasil, nessa quarta-feira (20), no Rio de Janeiro. A meta é fortalecer a produção nacional do medicamento e ampliar o acesso da população ao tratamento de doenças…

[tombeane-blog]

Pantone 13-1023 Just In Time For Christmas

I woke up this morning, logged onto the Google and was slapped with this horrific headline.

"El Nino appears to be on the verge of rapid collapse"

Holy c-rap! Rapid collapse? That can't be good, can it? Will we hear the sucking sound as it collapses - pulling in all the birds, fish and ships in the area along with that giant floating pile of plastic straws the size of Texas?

I can never remember exactly what El Nino means in terms of winter weather. I think El Ninos cause winter to be hotter and wetter… or maybe it's colder and drier?

On the other hand I just can't take La Nina seriously because it seems smaller and weaker - all girly or something.

Anyway, none of these seem like a good thing. I've been told nothing related to a changing climate can ever be good.

I mean we are supposed to spend 67 gazzilion dollars(adjusted for inflation) over the next X years keeping it from changing 1 or 2 degrees right?

So I ask myself, why do we put up with 20 degrees in the winter and 101 degrees in the summer? Can't we fix that too?

But I got off base here. Back to the headlines.

"The climate pattern known as El Niño, which quickly strengthened into a strong event, appears to be on the brink of a major decline, which would send the world into what is known as a neutral status."

Sending the world into Neutral Status? Are we supposed to think that is better? Somehow it sounds even scarier, or, at the least, more boring.

====================== Speaking of health hazards. How much do we know about what we put into our bodies?

Study the following list of ailments: Dizziness, headaches, nausea, diarrhea, constipation, blurred vision, hives, itching, fever, trouble breathing, drowsiness, insomnia, dry mouth, urinary tract infections (UTIs), genital infections, erection lasting 24 hours, dehydration, low blood sugar, ketoacidosis, alopecia, dermatitis, photosensitivity, dry skin, sweating… …and then there is low blood pressure, high blood pressure, no blood pressure… …and in rarely common cases - near death, far death, fear of death, fear of not dying and dying.

Now match them to the common medications we see on T.V. each and every day: Abilify, Jardiance, Rinvoq, Skyrizi, Viozah, DexcomG7, Dupixent, Jardiance, Celexa, Cialis, Celebrix, Claritin-D, Cosyntyx, Chantix, Lyrica, Lutada, Lexapro, Eliquis, Humira, Paxil, Zoloft, Xeljanz, Viibryd, Viagra and Voya (Not sure about that last one. It might be a financial thingy)

Ha! You just wasted three hours categorizing and cross referencing and fell for a titanius tower of trickery!

Most of them match most of them.

====================== While we are contemplating titanastic towers of stuff…

In the early twentieth century, New York City had a population of 7,000,000 humans and about 150,000+ horses. Each horse on average produced twenty-two pounds of manure a day, i.e., forty-five thousand tons of horse poop a month.

"Experts” at that time predicted that by 1930, the stuff would be piled three stories high in the streets. If asked, the "expert's" solution probably would have been to just kill all the horses.

As Yogi Berra once said, “Predictions are hard, especially about the future.” Because soon a technical solution in the form of the automobile came along.

Goodby poop smell! Hello sweet odor of automobile exhaust!

Maybe we should question "experts" a little more carefully and think through the "solutions" they push.

Like that deep throated guy in the movie 'All The President's Men' said, "Follow the money".

====================== Good news I just saw on the Telly! After the 87th attack on our forces in the Mideast, Our Secretary of Defense has just announced that the U.S. may be forced to taunt the Houthi's a second time.

====================== But I don't want to leave you feeling down just before The Holidays. So there's this:

"A warm and cozy shade highlighting our desire for togetherness with others and the feeling of sanctuary this creates, it presents a fresh approach to a new softness. Subtly sensual, it is a heartfelt hue bringing a feeling of tenderness and communicating a message of caring and sharing, community and collaboration."

I don't know about you but I'm feeling all tickly inside somewhere near my duodenum.

Yes. It's the 2024 Color Of The Year - PANTONE 13-1023 PEACH FUZZ.

Much better than 2023's color of the year - Gang Green. But, unlike Peach Fuzz, it is a Holiday color - sooo…

Merry Christmas!

[techninja]

Challenges and Opportunities in the DMARD Market: Balancing Efficacy, Safety, and Affordability

Introduction

The Disease-Modifying Antirheumatic Drug (DMARD) market is a critical segment of the pharmaceutical industry, playing a pivotal role in the management of autoimmune diseases, particularly rheumatoid arthritis. DMARDs are a class of medications that are designed to not only alleviate the symptoms of these debilitating diseases but also modify their course, potentially halting their progression. This market has witnessed substantial growth and innovation in recent years, making it a focal point in the global healthcare landscape.

Market Dynamics

1. Rising Prevalence of Autoimmune Diseases: The global DMARD market has experienced significant expansion due to the increasing prevalence of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. These conditions affect millions of people worldwide, necessitating effective treatment options.

2. Innovations in Drug Development: The DMARD market has seen a surge in research and development activities, leading to the introduction of novel drugs with enhanced efficacy and reduced side effects. Biologic DMARDs, in particular, have revolutionized the treatment of autoimmune diseases.

3. Expanding Geriatric Population: The aging global population is a major driver of the DMARD market. Autoimmune diseases often manifest in older individuals, and the demand for DMARDs is expected to grow in tandem with this demographic shift.

4. Patient-Centric Approach: Healthcare providers are increasingly focusing on providing patient-centric care. This involves tailoring DMARD treatments to individual patient needs, considering factors such as disease severity, comorbidities, and patient preferences.

Key Players

The DMARD market is highly competitive, with several prominent pharmaceutical companies leading the way. Some of the key players in this market include:

1. AbbVie Inc.: Known for their blockbuster DMARD, Humira, AbbVie has a strong presence in the market. They continue to invest in research and development to expand their portfolio.

2. Amgen Inc.: Amgen is a leader in biologic DMARDs, with Enbrel being one of their key products.

3. Pfizer Inc.: Pfizer's Xeljanz is a widely used DMARD, and they are actively working on developing new treatments.

4. Roche Holdings AG: Roche has a strong portfolio of DMARDs, with drugs like Rituxan and Actemra catering to the needs of patients.

Market Challenges

While the DMARD market shows great promise, it also faces several challenges:

1. High Costs: DMARDs, especially biologics, can be expensive, making access difficult for some patients. This issue raises concerns about healthcare equity.

2. Side Effects: Some DMARDs can have significant side effects, including an increased risk of infections and potential impact on other organ systems. Balancing the benefits and risks is a complex endeavor.

3. Regulatory Hurdles: The regulatory process for approving DMARDs is rigorous. Striking a balance between safety and timely approval can be challenging for pharmaceutical companies.

Market Outlook

The DMARD market is expected to continue its growth trajectory in the coming years. With ongoing research and development, the introduction of new and more effective treatments is likely. Advances in personalized medicine may allow for more tailored approaches to treatment, improving outcomes for patients.

Moreover, the market is expanding geographically, with increasing awareness of autoimmune diseases in developing countries. This, along with a growing geriatric population, will contribute to market expansion.

Conclusion

The Disease-Modifying Antirheumatic Drug (DMARD) market is pivotal in the management of autoimmune diseases, offering hope and improved quality of life to millions of patients worldwide. As innovation and research continue to drive progress in this field, the future looks promising. However, addressing challenges such as high costs and side effects remains essential to ensure equitable access to these life-changing therapies. With a focus on patient-centric care and ongoing global efforts, the DMARD market is poised for sustained growth and development in the years to come.

Few Other Promising Reports in Pharmaceutical Industry

Molecular Spectroscopy Market

Life Science Microscopy Devices Market

Process Spectroscopy Market

Drug Discovery Market